GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 57
- Registration Number
- NCT01920594
- Locations
- 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
Phase 3
Completed
- Conditions
- Fractures, Bone
- Interventions
- Biological: Denosumab 70 mg/mLDrug: Placebo IVDrug: Placebo SCDietary Supplement: Calcium supplementDietary Supplement: Vitamin D supplement
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 487
- Registration Number
- NCT01920568
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians
Completed
- Conditions
- Dermatitis, Atopic
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 160
- Registration Number
- NCT01920464
Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy
Phase 2
Completed
- Conditions
- Atherosclerosis
- Interventions
- Drug: SB-480848 40 mgDrug: SB-480848 80 mgDrug: Placebo
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 103
- Registration Number
- NCT01916720
A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 107
- Registration Number
- NCT01915914
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Duac™Once Daily Gel
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1018
- Registration Number
- NCT01915732
- Locations
- 🇨🇳
GSK Investigational Site, Wuhan, China
A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis
Phase 4
Completed
- Conditions
- Rhinitis, Allergic, Perennial and Seasonal
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 682
- Registration Number
- NCT01916226
- Locations
- 🇺🇸
GSK Investigational Site, Greenfield, Wisconsin, United States
W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: clindamycin1%/tretinoin 0.025% gelDrug: vehicle gel
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT01915758
Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01916200
Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Other: Data interpretation
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01915888
© Copyright 2025. All Rights Reserved by MedPath